New IDEXX CardioPet ECG Device Streamlines Work Flow to Facilitate Cardiac Consultations
Wireless device enables direct ECG transmission for easier collaboration with IDEXX Telemedicine Consultants
WESTBROOK, Maine, December 9, 2014 — IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced the launch of the CardioPet* ECG Device, making cardiac screenings, consultations and collaboration with the board-certified cardiologists of IDEXX Telemedicine Consultants even easier. With six leads and pet-friendly clips, the CardioPet ECG Device is DICOM compliant and offers improved diagnostic quality and patient comfort. What’s more, veterinarians can now view the electrocardiogram (ECG) to ensure the quality of tracings before submitting it. Submitting an ECG no longer requires a phone call, so practices can submit cases electronically at their convenience, day or night. In addition to facilitating direct ECG transmissions, veterinarians can combine ECGs, radiographs and/or echocardiograms in a single transmission when requesting a comprehensive cardiac consultation.
“The CardioPet* ECG Device makes it easy for clients to share all the information they have on a given case,” says Donald Schofield, General Manager of IDEXX Telemedicine Consultants. “Whether used for preoperative screenings or for managing cardiac cases, this information helps our cardiology team collaborate more fully with veterinarians. The result is advanced care for patients, which is everyone’s goal.”
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing livestock and poultry diagnostic tests and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 6,000 people and offers products to customers in more than 175 countries.
Note Regarding Forward-Looking Statements
This trade release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” and similar words and expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at , at various SEC reference facilities in the United States and via the Company’s website at ).